cabergoline has been researched along with Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous in 62 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 12 (19.35) | 29.6817 |
2010's | 39 (62.90) | 24.3611 |
2020's | 11 (17.74) | 2.80 |
Authors | Studies |
---|---|
Shi, H; Wu, D; Yu, T; Yu, Y; Zhai, J | 1 |
Karakus, C; Ozyurt, R; Turktekin, N | 1 |
Dahan, MH; Mills, G | 1 |
Bakırcı, Ş; Bulanık, M; Devrim, T; Gözüyukarı, H; Sağsöz, N; Şahin, Y | 1 |
Gulsen Coban, P; Haltas, H; Inal, HA; Timur, H; Yilmaz, N; Yilmaz, S | 1 |
Atabay, F; Ateş, Ç; Dilbaz, B; Ergani, SY | 1 |
Baba, K; Hayashi, N; Huang, H; Ichinose, S; Itaya, Y; Matsunaga, S; Narita, T; Ono, Y; Saitoh, M; Samejima, K; Seki, H; Takai, Y | 1 |
Erbas, O; Hortu, I; Karadadas, E; Ozceltik, G; Tavmergen Goker, EN; Tavmergen, E; Yigitturk, G | 1 |
Hart, RJ; Mourad, SM; Tang, H; Wang, A; Zhai, SD | 1 |
Hubka, Petr; Lincová, Marcela; Sehnal, Borek; Višňová, Hana; Zikán, Michal | 1 |
Elshaer, HS; Farouk, M; Fouda, UM; Hanafy, A; Mehrem, WM; Nabil, H; Youssef, GG; Youssef, MA | 1 |
Abdelsalam, EA; Elmahdy, M; Maghraby, HA | 1 |
Basly, M; Chibani, M; Haj Hassine, A; Jellad, S; Mrabet, A; Rachdi, R | 1 |
Amso, NN; D'Angelo, A; Hassan, R | 1 |
Bassiouny, YA; Bayoumi, YA; Dakhly, DMR; Gouda, HM; Hassan, AA; Salaheldin, NM | 1 |
Čehić, E; Franulić, D; Grgić, F; Kasum, M; Lila, A; Orešković, S; Vujić, G | 1 |
Hefzy, E; Seyam, E | 1 |
Celik, H; Celik, S; Hatirnaz, ES; Hatirnaz, S; Soyer-Calıskan, C; Tosun, M | 1 |
Atilgan, R; Başpınar, M; Ilhan, N; Pala, Ş; Yavuzkır, Ş; Yılmaz, M | 1 |
Çilgin, H | 1 |
El Maghraby, HA; El-Gezary, D; Gaafar, S | 1 |
Balayla, J; Dahan, MH; Shrem, G; Son, WY; Steiner, N; Tannus, S; Volodarsky-Perel, A | 1 |
Chen, HJ; Hsieh, BC; Huang, LW; Huang, MZ; Hwang, JL; Lin, YH; Seow, KM; Tzeng, CR | 1 |
Bai, CH; Chen, HJ; Hsieh, BC; Huang, LW; Hwang, JL; Lin, YH; Seow, KM; Tzeng, CR | 1 |
Bozdag, G; Esinler, I; Karakocsokmensuer, L | 1 |
Cinar, O; Dilbaz, S; Duraker, R; Guvendag Guven, ES; Mentese, A; Ozdegirmenci, O | 1 |
Deveer, R; Engin-Ustun, Y; Moraloglu, O; Timur, H; Ustun, Y; Yılmaz, N; Yılmaz, S | 1 |
Andrés, M; Expósito, A; Matorras, R; Mendoza, R; Pijoan, JI; Prieto, B | 1 |
Leitao, VM; Martins, WP; Moroni, RM; Nastri, CO; Seko, LM | 1 |
Beketić-Orešković, L; Ježek, D; Kasum, M; Orešković, S; Pekez, M; Stanić, P; Vrčić, H | 1 |
Angelova, M; Kacarova, P; Kozovski, G | 1 |
Akdogan, A; Akman, L; Aktug, H; Erbas, O; Goker, EN; Sahin, G; Taskiran, D; Tavmergen, E | 1 |
Adali, E; Balcioğlu, E; Erken, G; Hismiogulları, AA; Taskin, MI; Topcu, O; Yay, A | 1 |
Akan, Z; Cengiz, H; Eskicioğlu, F; Sahin, N; Sivrikoz, ON; Turan, GA; Vatansever, S; Yeşil, H; Yilmaz, O; Zafer, A | 1 |
Apaydın, N; Cengiz, H; Eskicioğlu, F; Genç, M; Şahin, N; Sivrikoz, ON; Töz, E; Turan, GA | 1 |
Cengiz, H; Eskicioğlu, F; Genc, M; Gur, EB; Kasap, E; Sivrikoz, ON; Turan, GA; Yılmaz, O | 1 |
Elsetohy, KA; Elshaer, HS; Fouda, UM; Hammad, BE; Sayed, AM; Shaban, MM; Youssef, MA | 1 |
El Tokhy, O; El-Toukhy, T; Kopeika, J | 1 |
Hart, RJ; Mourad, S; Tang, H; Zhai, SD | 1 |
Brown, J; Farquhar, C; Mourad, S | 1 |
Abdelmassih, R; Abdelmassih, S; Abdelmassih, V; Carizza, C; Jine, LT; Nagy, P; Ravizzini, P; Salgueiro, L; Salgueiro, PT | 1 |
Garcia-Velasco, JA | 1 |
Ata, B; Orhaner, S; Seyhan, A; Urman, B | 1 |
Amols, MH; Coddington, CC; Hudson, SBA; Rollene, NL | 1 |
Hwang, JL; Lin, YH; Seow, KM | 1 |
Arioz, DT; Dilek, H; Koken, T; Saylan, A; Saylan, F; Yilmazer, M | 1 |
Bourdel, N; Delabaere, A; Jardon, K; Pouly, JL; Tran, X | 1 |
Alcázar, JL; Monedero, P; Nagore Setién, D | 1 |
Delgado-Rosas, F; Ferrero, H; Gaytan, F; Gaytan, M; Gómez, R; Morales, C; Pellicer, A; Simón, C; Zimmermann, RC | 1 |
Arabipoor, A; Aziminekoo, E; Bahmanabadi, A; Chehrazi, M; Hafezi, M; Tehraninejad, ES | 1 |
Hart, RJ; Hu, Y; Hunter, T; Sheng, X; Tang, H; Zhai, SD | 1 |
Aleyasin, A; Bahmaee, F; Hosseini, MA; Mahdavi, A; Safdarian, L | 1 |
Shaltout, A; Shohyab, A; Youssef, MA | 1 |
Creatsas, G; Kalampokas, E; Kalampokas, T | 1 |
Adamo, V; Manno, M; Marchesan, E; Tomei, F | 2 |
Alonso-Muriel, I; Gomez, R; Gonzalez-Izquierdo, M; Novella-Maestre, E; Pellicer, A; Remohi, J; Sanchez-Criado, J; Simon, C; Zimmermann, RC | 1 |
Danilovic, DL; Knoepfelmacher, M; Mendonça, BB; Rosa Nasser, RH | 1 |
Alvarez, C; Fernández-Sánchez, M; Gómez, R; Martí-Bonmatí, L; Novella-Maestre, E; Pellicer, A; Sanz, R; Simón, C | 1 |
Aboulghar, MA | 1 |
Alonso-Muriel, I; Alvarez, C; Bellver, J; Crespo, J; García, G; Pellicer, A; Simón, C | 1 |
De Santis, L; Doldi, N; Ferrari, A; Marelli, G; Marsiglio, E; Papaleo, E; Rofena, S | 1 |
12 review(s) available for cabergoline and Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous
Article | Year |
---|---|
Comparison of the Effectiveness of Various Medicines in the Prevention of Ovarian Hyperstimulation Syndrome: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Cabergoline; Female; Humans; Network Meta-Analysis; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic | 2022 |
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Fertilization in Vitro; Humans; Live Birth; Ovarian Hyperstimulation Syndrome; Placebos; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic | 2021 |
Current possibilities in the prevention and therapy of ovarian hyperstimulation syndrome.
Topics: Cabergoline; Female; Fertilization in Vitro; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Polycystic Ovary Syndrome | 2021 |
Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Cabergoline; Chorionic Gonadotropin; Ergolines; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Live Birth; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Pregnancy, Multiple; Randomized Controlled Trials as Topic; Withholding Treatment | 2017 |
Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome
Topics: Aminoquinolines; Bromocriptine; Buserelin; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Estrogens; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Oocyte Retrieval; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Progesterone; Progestins; Triptorelin Pamoate | 2017 |
Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials.
Topics: Cabergoline; Ergolines; Female; Humans; Oocyte Retrieval; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted | 2014 |
Dopamine agonists in prevention of ovarian hyperstimulation syndrome.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction | 2014 |
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted | 2016 |
Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.
Topics: Cabergoline; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Metformin; Ovarian Hyperstimulation Syndrome; Pregnancy; Progesterone; Reproductive Techniques, Assisted; Review Literature as Topic | 2017 |
How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists.
Topics: Cabergoline; Clinical Protocols; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Randomized Controlled Trials as Topic | 2009 |
Cabergoline for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted | 2012 |
Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.
Topics: Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Evidence-Based Medicine; Female; Fertility Agents, Female; Gene Expression Regulation; Humans; Ovarian Hyperstimulation Syndrome; Ovary; Phosphorylation; Protein Processing, Post-Translational; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
16 trial(s) available for cabergoline and Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous
Article | Year |
---|---|
Cabergoline versus calcium infusion in the prevention of ovarian hyperstimulation syndrome: a randomised controlled study.
Topics: Adult; Cabergoline; Calcium Gluconate; Female; Fertilization in Vitro; Humans; Incidence; Infusions, Intravenous; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Prospective Studies; Single-Blind Method; Treatment Outcome | 2022 |
Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
Topics: Adult; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Female; Fertilization in Vitro; Humans; Ovarian Hyperstimulation Syndrome; Prospective Studies; Severity of Illness Index; Sperm Injections, Intracytoplasmic; Vascular Endothelial Growth Factor A | 2017 |
Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Sperm Injections, Intracytoplasmic | 2018 |
Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.
Topics: Adult; Cabergoline; Chemoprevention; Clomiphene; Drug Resistance; Ergolines; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Gynecologic Surgical Procedures; Hormone Antagonists; Humans; Infertility, Female; Laparoscopy; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Secondary Prevention; Treatment Failure | 2018 |
Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Risk Factors; Sperm Injections, Intracytoplasmic; Young Adult | 2019 |
Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Treatment Outcome | 2013 |
The effect of cabergoline on folicular microenviroment profile in patients with high risk of OHSS.
Topics: Adult; Anti-Mullerian Hormone; Cabergoline; Cellular Microenvironment; Cohort Studies; Ergolines; Female; Fertilization in Vitro; Follicular Fluid; Hepatocyte Growth Factor; Humans; Inhibins; Insulin-Like Growth Factor I; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Risk Factors; Young Adult | 2013 |
Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Hydroxyethyl Starch Derivatives; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Plasma Substitutes; Pregnancy; Pregnancy Rate; Prospective Studies; Secondary Prevention; Triptorelin Pamoate | 2013 |
Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
Topics: Animals; Cabergoline; Capillary Permeability; Chorionic Gonadotropin; Ergolines; Eye Proteins; Female; Gonadotropins, Equine; Humans; Letrozole; Nerve Growth Factors; Nitriles; Ovarian Hyperstimulation Syndrome; Ovary; Pregnancy; Prospective Studies; Rats; Rats, Wistar; Serpins; Triazoles; Vascular Endothelial Growth Factor A | 2016 |
GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
Topics: Adult; Antineoplastic Agents; Cabergoline; Chorionic Gonadotropin; Ergolines; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Incidence; Outcome Assessment, Health Care; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Young Adult | 2016 |
Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.
Topics: Adult; Albumins; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Female; Fertilization in Vitro; Humans; Oocytes; Ovarian Hyperstimulation Syndrome; Prospective Studies; Risk; Sperm Injections, Intracytoplasmic; Treatment Outcome | 2008 |
Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.
Topics: Adult; Cabergoline; Dopamine Agents; Ergolines; Female; Fertilization in Vitro; Humans; Incidence; Infertility; Infusions, Intravenous; Iran; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Outcome; Pregnancy Rate; Risk Factors; Serum Albumin; Serum Albumin, Human; Severity of Illness Index; Sperm Injections, Intracytoplasmic; Young Adult | 2012 |
Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Ovarian Hyperstimulation Syndrome; Pilot Projects; Young Adult | 2012 |
Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Sperm Injections, Intracytoplasmic | 2012 |
Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome?
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Treatment Outcome | 2005 |
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.
Topics: Adult; Ascites; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Extracellular Space; Female; Fertilization in Vitro; Granulosa Cells; Hematocrit; Hemoglobins; Humans; Image Processing, Computer-Assisted; Luteal Cells; Magnetic Resonance Imaging; Ovarian Hyperstimulation Syndrome; Ovary; Pregnancy; Prospective Studies; Receptors, Dopamine D2; Regional Blood Flow; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
34 other study(ies) available for cabergoline and Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous
Article | Year |
---|---|
Calcium gluconate infusion is not as effective as dopamine agonists in preventing ovarian hyperstimulation syndrome.
Topics: Cabergoline; Calcium Gluconate; Dopamine Agonists; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate | 2022 |
Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin.
Topics: Cabergoline; Chorionic Gonadotropin; Electrolytes; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Retrospective Studies; Vascular Endothelial Growth Factor A | 2022 |
Effect of ondansetron for preventing of ovarian hyperstimulation syndrome: in an experimental rat model.
Topics: Animals; Cabergoline; Dopamine Agonists; Endothelial Cells; Female; Humans; Ondansetron; Ovarian Hyperstimulation Syndrome; Rats; Rats, Wistar; Serotonin; Vascular Endothelial Growth Factor A | 2022 |
Does cabergoline administration affect endometrial VEGFR-2 expression in a rat model of ovarian hyperstimulation syndrome?
Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Female; Ovarian Hyperstimulation Syndrome; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2023 |
Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats.
Topics: Animals; Body Weight; Cabergoline; Female; Horses; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A | 2023 |
Late-onset ovarian hyperstimulation syndrome developing during ovarian stimulation in an ectopic pregnancy: a case report.
Topics: Adult; Cabergoline; Chorionic Gonadotropin; Estradiol; Female; Fertilization in Vitro; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy, Ectopic | 2020 |
Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
Topics: Animals; Cabergoline; Disease Models, Animal; Female; Ovarian Hyperstimulation Syndrome; Oxytocics; Oxytocin; Rats; Rats, Sprague-Dawley; Rats, Wistar; Vascular Endothelial Growth Factor A | 2021 |
Combining several interventions to reduce the incidence of OHSS: A prospective cohort study.
Topics: Adult; Aspirin; Cabergoline; Chorionic Gonadotropin; Drug Therapy, Combination; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Infertility, Female; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Reproductive Control Agents; Severity of Illness Index | 2017 |
Lifesaving dose increment of cabergoline in life-threatening spontaneous ovarian hyperstimulation syndrome resistant to all interventions.
Topics: Adult; Cabergoline; Dopamine Agonists; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Complications | 2019 |
What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model?
Topics: Animals; Anti-Bacterial Agents; Cabergoline; Chorionic Gonadotropin; Clarithromycin; Disease Models, Animal; Dopamine Agonists; Estradiol; Female; Gonadotropins, Equine; Interleukin-10; Interleukin-1beta; Ovarian Hyperstimulation Syndrome; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2019 |
Can a cyclooxygenase inhibitor be an option for treatment of ovarian hyperstimulation syndrome?
Topics: Animals; Cabergoline; Celecoxib; Cyclooxygenase Inhibitors; Female; Injections, Subcutaneous; Ovarian Hyperstimulation Syndrome; Rats; Rats, Wistar | 2019 |
Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome.
Topics: Adult; Buserelin; Cabergoline; Dopamine Agonists; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Retrospective Studies | 2019 |
Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.
Topics: Adult; Cabergoline; Cryopreservation; Embryo Transfer; Ergolines; Estradiol; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Retrospective Studies; Sperm Injections, Intracytoplasmic | 2013 |
Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Fertility Agents, Female; Fertilization in Vitro; Follicle Stimulating Hormone; Hormones; Humans; Infertility, Female; Leuprolide; Longitudinal Studies; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Retrospective Studies; Young Adult | 2013 |
Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Cabergoline; Cell Count; Disease Models, Animal; Drug Evaluation, Preclinical; Ergolines; Female; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovum; Rats; Rats, Wistar | 2013 |
[Use of cabergoline for prevention of ovarian hyperstimulation syndrome in assisted reproductive technologies].
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Pregnancy | 2014 |
Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
Topics: Acetates; Animals; Ascitic Fluid; Body Weight; Cabergoline; Capillary Permeability; Chorionic Gonadotropin; Cyclopropanes; Dopamine Agonists; Ergolines; Female; Gonadotropins, Equine; Horses; Humans; Immunohistochemistry; Leukotriene Antagonists; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Quinolines; Rats; Rats, Wistar; Reproductive Control Agents; Sulfides; Vascular Endothelial Growth Factor A | 2015 |
Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cabergoline; Ergolines; Estrogens; Female; Gonadotropin-Releasing Hormone; Interleukin-6; Ovarian Hyperstimulation Syndrome; Ovary; Progesterone; Ranibizumab; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A | 2015 |
Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study.
Topics: Acetates; Animals; Cabergoline; Chorionic Gonadotropin; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Ergolines; Female; Ovarian Hyperstimulation Syndrome; Ovary; Quinolines; Random Allocation; Rats; Rats, Wistar; Sulfides | 2015 |
Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model.
Topics: Animals; Antioxidants; Cabergoline; Disease Models, Animal; Dopamine Agonists; Ergolines; Female; Ovarian Hyperstimulation Syndrome; Ovary; Random Allocation; Rats; Rats, Wistar; Resveratrol; Stilbenes | 2016 |
An update on the prevention of ovarian hyperstimulation syndrome.
Topics: Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Estrogens; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Humans; Kisspeptins; Leuprolide; Luteinizing Hormone; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Recombinant Proteins; Reproductive Control Agents; Risk Assessment | 2016 |
High dose cabergoline in management of ovarian hyperstimulation syndrome.
Topics: Adult; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Severity of Illness Index; Treatment Outcome | 2009 |
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series.
Topics: Adult; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Treatment Outcome | 2009 |
Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Estradiol; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Treatment Failure | 2010 |
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
Topics: Analysis of Variance; Animals; Biopsy, Needle; Body Weight; Cabergoline; Chorionic Gonadotropin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Immunohistochemistry; Injections, Intramuscular; Meloxicam; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Pregnancy; Pregnancy, Animal; Probability; Random Allocation; Rats; Rats, Wistar; Thiazines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
[Spontaneous ovarian hyperstimulation syndrome in a pregnancy with hypothyroidism].
Topics: Abdominal Pain; Adrenal Cortex Hormones; Adult; Cabergoline; Chorionic Gonadotropin; Ergolines; Female; Fibrinolytic Agents; Follicle Stimulating Hormone; Gestational Age; Graves Disease; Humans; Hypothyroidism; Luteinizing Hormone; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Complications; Thyroidectomy; Thyrotropin | 2011 |
[Clinical utility of cabergoline in ovarian hyperstimulation syndrome].
Topics: Adult; Cabergoline; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome | 2011 |
Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment.
Topics: Adult; Cabergoline; Cells, Cultured; Dopamine; Dopamine Agonists; Ergolines; Female; Granulosa Cells; Humans; Luteal Cells; Neovascularization, Physiologic; Oocytes; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Receptors, Dopamine D2; Risk Factors; Signal Transduction; Tissue Banks; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2011 |
Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
Topics: Animals; Cabergoline; Capillary Permeability; Corpus Luteum; Disease Models, Animal; Dopamine Agonists; Ergolines; Female; Neovascularization, Physiologic; Ovarian Hyperstimulation Syndrome; Phosphorylation; Rats; Rats, Wistar; Receptors, Dopamine D2; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas.
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms | 2006 |
An important new adaption of a specific drug?
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Neovascularization, Pathologic; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms; Polycystic Ovary Syndrome; Vascular Endothelial Growth Factor A | 2007 |
Editorial: Preventing ovarian hyperstimulation syndrome.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Fertilization in Vitro; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2007 |
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study.
Topics: Adult; Cabergoline; Dopamine Agonists; Embryo Implantation; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pilot Projects; Pregnancy; Pregnancy Rate; Reproductive Techniques, Assisted; Retrospective Studies | 2007 |
Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome.
Topics: Adult; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Infertility, Female; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Recombinant Proteins; Time Factors; Ultrasonography | 2001 |